The Global Gene Silencing Market was valued at USD 9.6 billion in 2024 and is estimated to grow at a CAGR of 11.6% to reach USD 28.5 billion by 2034, driven by a rising global incidence of genetic diseases and rising demand for next-generation therapies. As more individuals are diagnosed with inherited conditions, the interest in treatments that modify or suppress disease-causing genes has accelerated. Healthcare systems are focusing on precision medicine, and gene silencing plays a crucial role in this shift, offering targeted therapeutic outcomes that conventional drugs cannot achieve. With improved biotechnological tools and stronger clinical pipelines, gene-based interventions are rapidly gaining traction among researchers and care providers.
The market has witnessed impressive technological strides, particularly with the adoption of advanced gene regulation methods. In 2024, the products segment held USD 7.7 billion, with continued expansion expected. Tools like CRISPR-Cas9, antisense oligonucleotides (ASOs), and RNA interference (RNAi) have proven vital in addressing genetic disorders at the molecular level. These technologies are unlocking new opportunities for targeted treatment, with ASOs showing promise in rare disease management and RNAi emerging as a platform for broader therapeutic applications.
Gene silencing market from the drug discovery and development segment captured 51% share in 2024 due to the growing use of RNAi and related technologies in research. Pharmaceutical and biotech companies are utilizing these tools to pinpoint disease-causing genes and streamline the early phases of drug development. The demand for gene-targeting platforms continues to grow as clinical trials for novel therapeutics expand across different therapeutic areas.
United States Gene Silencing Market is expected to reach USD 11.1 billion by 2034. The country’s robust research infrastructure, backed by leading firms such as Thermo Fisher Scientific, Agilent Technologies, and Bio-Rad Laboratories, supports steady innovation in gene silencing treatments. Ongoing R&D investment and regulatory support also contribute to a favorable growth environment. The country remains a hub for clinical advancements and funding in genomic medicine.
Key players such as Merck KGaA, GenScript, Revvity Discovery, Santa Cruz Biotechnology, and New England Biolabs are strengthening their market presence through focused investments in RNAi and ASO platforms. These companies are expanding their portfolios with gene editing tools, custom oligo synthesis, and scalable delivery systems. Strategic partnerships with academic institutions and biotech startups help them stay ahead in clinical innovation. Firms invest in automation, AI-based gene target screening, and enhanced laboratory infrastructure to speed up research cycles. Continuous efforts to secure regulatory approvals and develop companion diagnostics are also central to competitiveness. By aligning product innovation with precision therapy trends, these companies capitalize on the growing need for targeted genetic treatments.
This product will be delivered within 2-4 business days.
The market has witnessed impressive technological strides, particularly with the adoption of advanced gene regulation methods. In 2024, the products segment held USD 7.7 billion, with continued expansion expected. Tools like CRISPR-Cas9, antisense oligonucleotides (ASOs), and RNA interference (RNAi) have proven vital in addressing genetic disorders at the molecular level. These technologies are unlocking new opportunities for targeted treatment, with ASOs showing promise in rare disease management and RNAi emerging as a platform for broader therapeutic applications.
Gene silencing market from the drug discovery and development segment captured 51% share in 2024 due to the growing use of RNAi and related technologies in research. Pharmaceutical and biotech companies are utilizing these tools to pinpoint disease-causing genes and streamline the early phases of drug development. The demand for gene-targeting platforms continues to grow as clinical trials for novel therapeutics expand across different therapeutic areas.
United States Gene Silencing Market is expected to reach USD 11.1 billion by 2034. The country’s robust research infrastructure, backed by leading firms such as Thermo Fisher Scientific, Agilent Technologies, and Bio-Rad Laboratories, supports steady innovation in gene silencing treatments. Ongoing R&D investment and regulatory support also contribute to a favorable growth environment. The country remains a hub for clinical advancements and funding in genomic medicine.
Key players such as Merck KGaA, GenScript, Revvity Discovery, Santa Cruz Biotechnology, and New England Biolabs are strengthening their market presence through focused investments in RNAi and ASO platforms. These companies are expanding their portfolios with gene editing tools, custom oligo synthesis, and scalable delivery systems. Strategic partnerships with academic institutions and biotech startups help them stay ahead in clinical innovation. Firms invest in automation, AI-based gene target screening, and enhanced laboratory infrastructure to speed up research cycles. Continuous efforts to secure regulatory approvals and develop companion diagnostics are also central to competitiveness. By aligning product innovation with precision therapy trends, these companies capitalize on the growing need for targeted genetic treatments.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Type, 2021-2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Application, 2021-2034 ($ Mn)
Chapter 7 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)
Chapter 9 Company Profiles
Companies Mentioned
The companies featured in this Gene Silencing market report include:- Agilent Technologies
- Bio-Rad Laboratories
- Cellecta
- Danaher
- GenScript
- Merck KGaA
- New England Biolabs
- Qiagen
- Revvity Discovery
- Santa Cruz Botechnology
- Thermo Fisher Scientific
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 138 |
| Published | May 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 9.6 Billion |
| Forecasted Market Value ( USD | $ 28.5 Billion |
| Compound Annual Growth Rate | 11.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
